NCT01025830View on ClinicalTrials.gov

Triomune Bioequivalence With Innovators

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

June 30, 2006

Study Completion Date

March 31, 2008

Conditions
HIV/AIDS
Interventions
DRUG

Triomune

Stavudine (40mg) Lamivudine (150mg) Nevirapine (200mg)All twice a day

DRUG

Zerit/Epivir/Viramune

Stavudine (40mg) Lamivudine (150mg) and Nevirapine (200mg) All taken twice daily.

Trial Locations (1)

Unknown

Makerere University, Kampala

All Listed Sponsors
collaborator

University of California, San Francisco

OTHER

lead

Makerere University

OTHER

NCT01025830 - Triomune Bioequivalence With Innovators | Biotech Hunter | Biotech Hunter